| Ruta graveolens extract induces DNA damage pathways and blocks Akt activation to inhibit cancer cell proliferation and survival K Fadlalla, A Watson, T Yehualaeshet, T Turner, T Samuel Anticancer research 31 (1), 233-241, 2011 | 68 | 2011 |
| Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells T Samuel, K Fadlalla, L Mosley, V Katkoori, T Turner, U Manne Anticancer research 32 (1), 61-71, 2012 | 52 | 2012 |
| Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs T Samuel, K Fadlalla, DN Gales, BDK Putcha, U Manne BMc cancer 14, 1-11, 2014 | 36 | 2014 |
| The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle T Samuel, K Fadlalla, T Turner, TE Yehualaeshet Nutrition and cancer 62 (8), 1025-1035, 2010 | 33 | 2010 |
| Bio-based calcium carbonate (CaCO3) nanoparticles for drug delivery applications D Render, VK Rangari, S Jeelani, K Fadlalla, T Samuel International Journal of Biomedical Nanoscience and Nanotechnology 3 (3 …, 2014 | 19 | 2014 |
| Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours S Rodriguez, K Fadlalla, T Graham, B Tameru, CD Fermin, T Samuel Journal of comparative pathology 147 (2-3), 171-176, 2012 | 16 | 2012 |
| 3-(2-Bromoethyl)-indole inhibits the growth of cancer cells and NF-κB activation K Fadlalla, R Elgendy, E Gilbreath, SR Pondugula, T Yehualaeshet, ... Oncology reports 34 (1), 495-503, 2015 | 8 | 2015 |
| Novel sulindac derivatives for colorectal cancer chemoprevention that target cGMP phosphodiesterases to suppress Wnt/β-catenin transcriptional activity S Ramesh, P Johnson, K Fadlalla, A Moore, CH Huang, K Berry, ... Cancer Insight 3 (1), 42-54, 2023 | 2 | 2023 |
| Novel Pan-RAS inhibitor ADT-007: A unique mechanism of antitumor selectivity in pancreatic and colorectal carcinoma models J Wang, AB Keeton, S Ramesh, P Johnson, YY Maxuitenko, JB Foote, ... Cancer Research 84 (6_Supplement), 3323-3323, 2024 | 1 | 2024 |
| ADT-007 binds RAS and inhibits RAS signaling AB Keeton, X Chen, J Valiyaveettil, CH Huang, TE Mattox, K Fadlalla, ... Cancer Research 83 (7_Supplement), 1658-1658, 2023 | 1 | 2023 |
| Modulation of tumor suppressor gene DNA-methylation by quercetin and dietary indoles T Samuel, K Fadlalla, T Yehualaeshet, T Turner Cancer Research 71 (8_Supplement), 2005-2005, 2011 | 1 | 2011 |
| ADT-030 is a novel dual-acting RAS/β-catenin inhibitor that potentiates antitumor immunity MY Gazi, O Okoko, X Wang, C Brandle, X Chen, K Fadlalla, A Keeton, ... Cancer Research 84 (6_Supplement), 2459-2459, 2024 | | 2024 |
| Abstract LB_B26: Efficacy and tolerability of a novel pan-RAS inhibitor with a unique mechanism of selectivity in mouse models of pancreatic cancer AB Keeton, YY Maxuitenko, JB Foote, CH Huang, KL Berry, K Fadlalla, ... Molecular Cancer Therapeutics 22 (12_Supplement), LB_B26-LB_B26, 2023 | | 2023 |
| Abstract LB322: Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma YY Maxuitenko, JB Foote, AB Keeton, X Chen, K Berry, K Fadlalla, ... Cancer Research 83 (8_Supplement), LB322-LB322, 2023 | | 2023 |
| Cancer Insight S Ramesh, P Johnson, K Fadlalla, A Moore, CH Huang, K Berry, ... Cancer 2 (2), 42-54, 2023 | | 2023 |
| 99 Temporal and spatial characterization of interleukin-6 protein in the caprine testis K Fadlalla Journal of Animal Science 97 (Suppl 3), 83, 2019 | | 2019 |
| Characterization of interleukin-6 in the caprine testis K Fadlalla, E Gilbreath, O Bolden-Tiller Animal Reproduction Science 194, e23, 2018 | | 2018 |
| Anticancer treatment methods involving analogs and derivatives of 3-(2-substituted-ethyl) indole compounds T Samuel, T Yehualaeshet, T Serbessa, K Fadlalla US Patent 9,877,949, 2018 | | 2018 |
| Bio-based calcium carbonate (CACO3) nanoparticles for drug delivery applications S Rangari, D Render, K Fadlalla, T Samuel Journal of the Alabama Academy of Science 86 (2), 135-137, 2015 | | 2015 |
| Abstract B11: Stromal response to prostate cancer therapeutics DN Gales, K Fadlalla, U Manne, C Yates, T Samuel Clinical Cancer Research 21 (4_Supplement), B11-B11, 2015 | | 2015 |
